Colleagues, as most of you know, text mining is the process to derive high quality structured information from unstructured text, (more…)
Pharma R&D Today
Ideas and Insight supporting all stages of Drug Discovery & Development
Posted on March 31st, 2016 by David EvansChemistry
I’ve just returned home from the 251st American Chemical Society (ACS) Meeting and Exposition in San Diego. While recovering from my jet lag, (more…)
Posted on March 29th, 2016 by Tim HoctorPharma R&D
Posted on March 24th, 2016 by Christy J. WilsonPharma R&D
You might think this is the opening line for a riddle, but in fact it forms the basis of IDEA Pharma’s Productive Innovation Index (PII for short), an annual ranking of the top 30 biopharmaceutical companies (more…)
Posted on March 21st, 2016 by Tim HoctorPharma R&D
Those outside of the drug and medical research communities often do not understand the complexities and challenges in developing therapeutic treatments for diseases that (more…)
Data Transparency in Pharmacovigilance: European regulators give increased access to adverse drug reactions
Posted on March 16th, 2016 by Joyce de LangenPharma R&D
On 17 December 2015, the European Medicines Agency (EMA) adopted the revised policy on access to Eudravigilance. According to the press release, the EMA will give increased access to reports of adverse reactions (more…)
About this Blog
The Elsevier Pharma R&D blog provides insight and opinion on topics related to pharmaceutical research and development, namely: big data, target identification, new drug discovery, drug safety monitoring, risk mitigation and regulatory compliance. We serve the community of chemists, scientists, drug safety specialists, educators and students interested in pharmaceutical R&D.
Editor’s note: The views and opinions expressed are those of the author and do not necessarily reflect the views of Elsevier, its affiliates and sponsors or its parent company, Reed Elsevier.